SPRB
Spruce BiosciencesCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
Current thesis
The bull case is that TA-ERT has a clearer FDA path after the Type B meetings, the Q4 2026 BLA target is achieved, and investors begin underwriting first-mover value in MPS IIIB plus access to milestone-linked debt capital.
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +1.1.
What can break
Additional Avenue debt tranches are milestone-gated rather than fully committed upfront.
Momentum
6
Value
41
Sentiment
100
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $72.00 · Bull $120.00 · Bear $34.00
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-21
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $151.00
Why
Momentum6 · Δ7d -2.6
Value41 · Δ7d +0.1
Sentiment100 · Δ7d +1.1
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Sentiment · See AI snapshot
Momentum
6
26% active weight
Current posture
7d trendSoftening
Δ7d
-2.6
Δ21d
-16.9
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
-0.0
Sentiment
100
34% active weight
Current posture
7d trendImproving
Δ7d
+1.1
Δ21d
+21.8
Why this grade
Composite grade C. Momentum 6.2 / Value 41.1 / Sentiment 100.0
Fundamentals (TTM)As of 2026-07-21
Fundamentals (TTM)
As of 2026-07-21
Market Cap
$125.72M
Beta
3.59
Shares Out
2.75M
P/E (TTM) · Derived
-0.9
P/S (TTM)
126.11
P/FCF (TTM) · Derived
-1.29
Rev YoY
-100.0%
EPS YoY
-62.7%
Gross Margin
+96.4%
Op Margin
-7100.0%
Net Debt
-$48.17M
Current Ratio
4.67
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology